ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
12.58
+0.09 (0.68%)
Mar 31, 2025, 1:23 PM EDT - Market open
ARS Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ARS Pharmaceuticals stock have an average target of 28.75, with a low estimate of 27 and a high estimate of 30. The average target predicts an increase of 128.63% from the current stock price of 12.58.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ARS Pharmaceuticals stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Initiates $30 | Buy | Initiates | $30 | +138.57% | Mar 7, 2025 |
| Raymond James | Raymond James | Strong Buy Maintains $26 → $28 | Strong Buy | Maintains | $26 → $28 | +122.66% | Jan 14, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $26 → $27 | Buy | Maintains | $26 → $27 | +114.71% | Jan 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +138.57% | Oct 8, 2024 |
| Leerink Partners | Leerink Partners | Buy Maintains $21 → $25 | Buy | Maintains | $21 → $25 | +98.81% | Sep 20, 2024 |
Financial Forecast
Revenue This Year
126.14M
from 89.15M
Increased by 41.49%
Revenue Next Year
227.34M
from 126.14M
Increased by 80.23%
EPS This Year
-1.11
from 0.08
EPS Next Year
-0.22
from -1.11
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 202.1M | 319.0M | 409.5M | ||
| Avg | 126.1M | 227.3M | 314.6M | ||
| Low | 80.5M | 151.1M | 228.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 126.7% | 152.9% | 80.1% | ||
| Avg | 41.5% | 80.2% | 38.4% | ||
| Low | -9.7% | 19.7% | 0.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.39 | 0.05 | 0.84 | ||
| Avg | -1.11 | -0.22 | 0.40 | ||
| Low | -1.52 | -0.59 | -0.21 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.